Sorrento Therapeutics, Inc. (SRNE): Marketing Mix Analysis [Dec-2025 Updated]

You're likely looking at Sorrento Therapeutics, Inc. (SRNE) expecting a deep dive into drug launches, but honestly, the story has completely flipped. As an analyst who's seen a few corporate turnarounds-and wind-downs-I can tell you that as of late 2025, the 4 Ps aren't about selling medicine anymore; they're about asset recovery. Instead of a product pipeline, the offering is now a stake in Vivasor, Inc. and the outcome of court-approved asset sales, with the common stock trading for pennies, maybe around $0.0035 to $0.0041 per share. Forget billboards and sales reps; the 'Place' is the U.S. Bankruptcy Court, and 'Promotion' is just mandatory legal filings. So, if you want to know what the real marketing mix is for a company in Chapter 11 wind-down, stick around; we're breaking down the liquidation strategy that dictates every remaining value point.

Sorrento Therapeutics, Inc. (SRNE) - Marketing Mix: Product

The product element for Sorrento Therapeutics, Inc. (SRNE) as of late 2025 is defined by its status as a wind-down entity under a court-approved liquidation plan.

Remaining assets consist primarily of cash reserves, active litigation claims, and intellectual property (IP) that has not yet been sold through the liquidation process. The Liquidating Trust is actively pursuing litigation, including a claim against former directors and officers seeking damages related to the Scilex Holding Co. stock dividend, which occurred while the company was allegedly facing a $173 million arbitration judgment.

The primary shareholder distribution product is a 7% equity stake in the private company Vivasor, Inc.. This stake represents the pro-rata distribution of value from specific assets acquired by Vivasor, Inc. from Sorrento Therapeutics, Inc. on March 8, 2024, for a total purchase price of $1.8 million in cash. Analysts estimate the potential enterprise value of Vivasor's IP could reach $100-200M within 2-3 years, which would place the value of the 7% shareholder stake in the range of $7-14M total, translating to approximately $0.035-0.07 per original SRNE share. Vivasor, Inc. is reportedly prioritizing the TNT119 CAR-T program for a Phase 1 trial restart in 2026.

Commercial products such as ZTlido® and SEMDEXA™ are no longer direct offerings of Sorrento Therapeutics, Inc. but are managed by its former subsidiary, Scilex Holding Company (SCLX). The core of SCLX's commercial portfolio includes:

• ZTlido® (1.8% lidocaine topical system) for neuropathic pain associated with postherpetic neuralgia (PHN).
• ELYXYB® (celecoxib oral solution) for the acute treatment of migraine in adults.
• GLOPERBA® (colchicine USP) for the prophylaxis of painful gout flares in adults.

SEMDEXA™ (SP-102), a non-opioid injectable corticosteroid gel formulation for lumbosacral radicular pain (sciatica), remains a key developmental candidate for SCLX. As of August 13, 2025, SCLX Common Stock was trading at $21.00 per share, and its Public Warrants (SCLXW) closed at $0.56.

The core offering of the Sorrento Therapeutics, Inc. entity itself is the recovery of value for creditors and shareholders through the administration of the Liquidating Trust. The trading restrictions on the former Sorrento common stock were sought to be extended until September 25, 2025, to preserve Tax Attributes and continue to seek a value-maximizing transaction for the estate.

The commercial assets managed by Scilex Holding Company can be summarized as follows:

Sorrento Therapeutics, Inc. (SRNE) - Marketing Mix: Place

You're looking at the distribution strategy for Sorrento Therapeutics, Inc. (SRNE) in late 2025, which is entirely dictated by its Chapter 11 wind-down process. The physical movement of the company's remaining assets and the market access for its former equity are highly controlled legal mechanisms, not traditional commercial distribution channels.

The central operating location for all distribution and asset realization activities is the U.S. Bankruptcy Court for the Southern District of Texas. The joint administration of the bankruptcy cases falls under Case No. 23-90085, presided over by the Honorable Christopher M. Lopez. This court dictates the terms under which any remaining value is realized and distributed.

Stock trading for Sorrento Therapeutics, Inc. occurs on the restricted OTC Expert Market under the symbol SRNE. This market designation means quotations are restricted from public viewing, and the stock is not eligible for proprietary broker-dealer quotations; all available quotes reflect only unsolicited customer orders. As of December 4, 2025, the stock price was reported at $0.0035. The market capitalization, as of early December 2025 filings, hovered around $2.76 million. The trading volume averaged approximately 138,014 shares daily. The trading of common stock has been subject to restrictions, with a motion filed in March 2025 to extend these restrictions beyond March 25, 2025, to preserve Tax Attributes.

Asset distribution channels are managed exclusively by the court-approved Liquidating Trust and its administrative processes. The primary focus of the Trust's distribution efforts involves resolving litigation over avoidable transfers, specifically the Scilex stock distributed to Debtors' shareholders. The Trust is pursuing claims against recipients of this stock, which was distributed when Sorrento was allegedly insolvent. The Trust is administering the process based on creditor claims, which aggregated over $1.4 billion, although the Trust estimated the allowable total to be closer to $200 to $300 million. The Trust filed its Chapter 11 Post-Confirmation Report for the quarter ended 9/30/2025 on 10/15/2025.

The corporate headquarters address now serves a nominal legal service function for the wind-down. The service address listed in court documents is 4955 Directors Place, San Diego, CA, 92121.

Here are the key operational metrics governing the 'Place' of distribution as of late 2025:

The distribution of any final proceeds is entirely contingent upon the Liquidating Trust's success in recovering value through litigation, particularly concerning the Scilex stock transfers. You can see the structure of the Trust's administrative filings here:

• Liquidating Trustee Counsel: NORTON ROSE FULBRIGHT US LLP
• Trust Service Address: 708 Main Street, 10th Floor, Houston, Texas 77002 (for settlement correspondence)
• Debtors' Service Address: 4955 Directors Place, San Diego, CA, 92121
• Trading Restriction Extension Sought Beyond: March 25, 2025

Honestly, the 'Place' for Sorrento Therapeutics, Inc. is a courtroom docket, not a shelf in a store.

Finance: review the latest Docket No. 2658 filing from 10/15/2025 to project potential recovery percentages for unsecured creditors by next Tuesday.

Sorrento Therapeutics, Inc. (SRNE) - Marketing Mix: Promotion

You're looking at the promotional landscape for Sorrento Therapeutics, Inc. (SRNE) as of late 2025, and honestly, it's entirely dictated by the ongoing Chapter 11 proceedings in the Southern District of Texas, Case No. 23-90085.

Communication is limited to mandatory Post-confirmation Reports filed with the Bankruptcy Court.

The only formal, recurring communication stream that functions like a mandated report is the Chapter 11 Post-Confirmation Report. For instance, the Liquidating Trustee filed the Chapter 11 Post-Confirmation Report for the Quarter Ending Date: 09/30/2025 on 10/15/2025. This document, filed by the Trustee, David Weinhoffer, serves as the primary source of operational and financial updates to the court and stakeholders post-plan confirmation.

Primary public relations are legal notices and updates from the Liquidating Trustee to stakeholders.

Public relations, in the traditional sense, is non-existent. What you see instead are legally required disclosures and actions taken by the Liquidating Trustee to maximize estate value. A significant recent example includes the Trustee suing former directors and officers for breach of fiduciary duty in July 2025. Furthermore, the Trustee sought court approval to extend trading restrictions on Sorrento's common stock, with an Emergency Hearing taking place no later than March 25, 2025.

Key dates related to these mandatory communications include:

• Petition Date for Chapter 11: February 13, 2023.
• Plan Effective Date: April 10, 2024.
• Filing of Q3 2025 Post-Confirmation Report: October 15, 2025.
• Extension of Scilex Dividend Stock Lockup Period: Set to expire April 14, 2025.

No commercial advertising or direct-to-consumer marketing for any drug product.

Given the liquidation status under Chapter 11, there is a complete absence of any commercial advertising or direct-to-consumer marketing efforts for any drug product. The focus is entirely on asset realization and litigation, not market penetration or sales promotion for unapproved or existing assets.

Investor relations are defintely non-existent outside of bankruptcy case information lines.

Traditional investor relations functions, like earnings calls or proactive shareholder outreach, have ceased. The sole point of contact for stakeholders seeking information about the bankruptcy case is the dedicated case information line. You can reach them via:

• Toll-free number: 833.278.6637.
• International number: 949.471.0454.

Any other information flow is channeled through official filings in the Bankruptcy Court docket, such as the one filed on 11/18/2025 regarding a hearing continuance.

Here's a quick look at the financial snapshot provided within the most recent mandatory filing, the Post-Confirmation Report for the Quarter Ended 9/30/2025. This data reflects the Trustee's post-confirmation administration, not commercial operations.

And to give you a sense of the costs associated with winding down the estate, here are the cumulative preconfirmation professional fees paid out of the estate assets, which are a key component of the liquidation process:

Finance: review the cash flow projections against the Q3 2025 disbursements by end of day Tuesday.

Sorrento Therapeutics, Inc. (SRNE) - Marketing Mix: Price

You're looking at the pricing structure for Sorrento Therapeutics, Inc. (SRNE) assets in this late 2025 environment, which is heavily influenced by the ongoing liquidation process. The pricing here isn't about consumer goods; it's about the value realized from asset sales and the nominal price of the remaining common stock.

The common stock trades at a very nominal price, reflecting its status post-restructuring. As of the close on December 4, 2025, the share price settled at $0.0035 per share. That was down from the prior day's close of $0.0041.

We can map out some of the recent trading activity to give you a clearer picture of this pricing:

• 52-week high for SRNE was $0.0985.
• 52-week low was $0.000066.
• The stock experienced a 110.00% fluctuation between its high and low on the last trading day.

Asset valuation, for the purpose of realizing creditor/shareholder value, is anchored to court-approved sale prices. For instance, a specific portfolio of intellectual property (IP) sold to Vivasor, Inc. was valued at $1.8 million in cash via a court-approved agreement from March 2024.

Here's a look at how key asset realization prices compare:

The pricing strategy for the former stake in Scilex Holding Company was established during the Chapter 11 proceedings. The Bankruptcy Court approved a $105 million 'stalking horse' bid from Oramed Pharmaceuticals, Inc. for substantially all of Sorrento Therapeutics, Inc.'s equity interests in Scilex back in August 2023. The final consideration for the securities transfer in September 2023 was $110 million, which included cash and the assumption of a senior secured term loan facility.

Regarding the liquidation costs, while the outline suggested a specific figure, the publicly available data closest to the liquidation process shows the context of asset realization. The price of the company's former stake in Scilex was valued at over $105 million in a 2023 stalking horse bid. That's a significant anchor point for the remaining asset value calculations.